NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe, effective, and naturally derived psychedelic therapies for people living with serious mental health challenges. Over the past few months, Psyence BioMed (PBM) has made meaningful progress across several fronts: clinical development, strategic positioning, regulatory compliance, and manufacturing stability. Thes ...

Business Combination Highlights - Non-atai Beckley Psytech shareholders will receive approximately 105 million newly issued shares of atai common stock, representing about 31% of the pro forma entity[14] - Closing is expected in the second half of 2025, pending atai shareholder approval[14] - Approximately 25% of atai's common stock has entered into voting agreements supporting the transaction[14] BPL-003 Clinical Trial Results and Design - Phase 1 results showed perceptual effects generally resolving in under 90 minutes[40] - Phase 2a Part 1 (Monotherapy Cohort) data showed a mean MADRS reduction of approximately 13 points at Day 2, sustained to Day 85[53] - In Phase 2a Part 1, 55% of patients met response criteria one day after a single 10mg dose of BPL-003[53] - In Phase 2a Part 1, 55% of patients met clinical remission criteria one month after a single dose, with 45% meeting remission criteria at day 85[53] - In Phase 2a, approximately 90% of drug-related AEs occurred on the day of dosing, and all were resolved without intervention[60] - Phase 2b clinical trial is a randomized, quadruple-masked, monotherapy study in approximately 196 moderate to severe TRD patients[62] Market Opportunity - SPRAVATO achieved blockbuster status in 2024 with sales exceeding $1 billion, with approximately 86% of sales in the US[24] - Johnson & Johnson highlights SPRAVATO as a "key franchise" guiding $3 billion to $3.5 billion in annual sales[28]